Farmakoterapia choroby Alzheimera i innych otępień w praktyce: który lek, kiedy i dla kogo?

• Authors: Marcin Wojtera , Tomasz Sobów

Title variants

EN

Pharmacotherapy in Alzheimer’s disease and other dementias in practical settings: which drug, when and for whom?

• Languages of publication: EN PL

Abstracts

EN

Dementia is characterised by a combination of different types of cognitive impairment, which is so significant that it affects daily living, disrupts patients’ professional activity and leads to complete dependence on relatives or adequate institutions. Dementias are usually caused by neurodegenerative processes or damage of vascular origin within the central nervous system. Alzheimer’s disease, which is fatal and progressive, is the main cause of dementia. Drugs used in modern medicine have only symptomatic effects and have no influence on the cause of the illness. Drugs registered for Alzheimer’s disease treatment (cholinesterase inhibitors and memantine) have been available for many years. The majority of doctors involved in treating dementia believe that they are well acquainted with the above substances which they often use. In clinical trials, it has been proven that the drugs have a moderate influence on cognitive functions, behavioural and psychological symptoms of dementia, and on activities of daily living. The influence of the drugs on the natural course of the disease in the central nervous system is still a controversial issue. This article discusses the clinical use of anti-dementia drugs available in Poland and practical recommendations regarding their choice in daily practice. Moreover, current recommendations for a change of the therapy (to a different inhibitor), combination therapy (cholinesterase inhibitors and memantine) and necessary safety procedures (contraindications, interactions) are presented.

PL

Dementia is characterised by a combination of different types of cognitive impairment, which is so significant that it affects daily living, disrupts patients’ professional activity and leads to complete dependence on relatives or adequate institutions. Dementias are usually caused by neurodegenerative processes or damage of vascular origin within the central nervous system. Alzheimer’s disease, which is fatal and progressive, is the main cause of dementia. Drugs used in modern medicine have only symptomatic effects and have no influence on the cause of the illness. Drugs registered for Alzheimer’s disease treatment (cholinesterase inhibitors and memantine) have been available for many years. The majority of doctors involved in treating dementia believe that they are well acquainted with the above substances which they often use. In clinical trials, it has been proven that the drugs have a moderate influence on cognitive functions, behavioural and psychological symptoms of dementia, and on activities of daily living. The influence of the drugs on the natural course of the disease in the central nervous system is still a controversial issue. This article discusses the clinical use of anti-dementia drugs available in Poland and practical recommendations regarding their choice in daily practice. Moreover, current recommendations for a change of the therapy (to a different inhibitor), combination therapy (cholinesterase inhibitors and memantine) and necessary safety procedures (contraindications, interactions) are presented.

Keywords

EN

Alzheimer’s disease; cholinesterase inhibitors; choroba Alzheimera; dementia; inhibitory acetylocholinesterazy; leczenie; memantine; memantyna; otępienie; treatment

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Aktualności Neurologiczne
• Year: 2014
• Volume: 14
• Issue: 4
• Pages: 218–227

Contributors

author

Marcin Wojtera

• Oddział Psychogeriatrii, Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodzi

author

Tomasz Sobów

• Oddział Psychogeriatrii, Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodzi. Zakład Psychologii Lekarskiej, Wydział Nauk o Zdrowiu, Uniwersytet Medyczny w Łodzi

References

• Aarsland D, Ballard C, Walker Z et al.: Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8: 613-618.
• Barcikowska M: Choroba Alzheimera. In: Rozpoznawanie i leczenie otępień. Rekomendacje Interdyscyplinarnej Grupy Ekspertów Rozpoznawania i Leczenia Otępień (IGERO 2006). Wydawnictwo Czelej, Lublin 2006: 34-51.
• Bartus RT, Dean RL 3rd, Beer B et al.: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-417.
• Carreiras MC, Mendes E, Perry MJ et al.: The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Curr Topics Med Chem 2013; 13: 1745-1770.
• Christensen K, Thinggaard M, Oksuzyan A et al.: Physical and cognitive functioning of people older than 90 years: a comparison of two Danish cohorts born 10 years apart. Lancet 2013; 382: 1507-1513.
• Cortes F, Gillette-Guyonnet S, Nourhashemi F et al.: Recent data on the natural history of Alzheimer's disease: results from the REAL. FR Study. J Nutr Health Aging 2005; 9: 86-93.
• Cummings J, Froelich L, Black SE et al.: Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higherdose rivastigmine patch (15 vs. 10 cm2) in Alzheimer's disease. Dement Geriatr Cogn Disord 2012; 33: 341-353.
• Cummings JL, Koumaras B, Chen M et al.: Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 2005; 3: 137-148.
• Daiello LA, Ott BR, Lapane KL et al.: Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother 2009; 7: 74-83.
• Danysz W, Parsons CG, Mobius HJ et al.: Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease - a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res 2000; 2: 85-97.
• Davies P, Maloney AJ: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403.
• Del Ser T, McKeith I, Anand R et al.: Dementia with Lewy bodies: findings from an international multicentre study. Int J Geriatr Psychiatry 2000; 15: 1034-1045.
• Droogsma E, van Asselt DZ, van Steijn JH et al.: Effect of long-term treatment with galantamine on weight of patients with Alzheimer's dementia. J Nutr Health Aging 2013; 17: 461-465.
• Emre M, Tsolaki M, Bonuccelli U et al.: Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 969-977.
• Farlow MR, Grossberg GT, Sadowsky CH et al.: A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia. CNS Neurosci Ther 2013; 19: 745-752.
• Farlow MR, Lilly ML; ENA713 B352 Study Group: Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC Geriatr 2005; 5: 3.
• Farlow MR, Miller ML, Pejovic V: Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord 2008; 25: 408-422.
• Ferri CP, Prince M, Brayne C et al.: Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-2117.
• Francis PT, Palmer AM, Snape M et al.: The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66: 137-147.
• Gauthier S, Emre M, Farlow MR et al.: Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin 2003; 19: 707-714.
• Ghezzi L, Scarpini E, Galimberti D: Disease-modifying drugs in Alzheimer's disease. Drug Des Devel Ther 2013; 7: 1471-1478.
• Gillette-Guyonnet S, Cortes F, Cantet C et al.; REAL.FR Group: Long-term cholinergic treatment is not associated with greater risk of weight loss during Alzheimer's disease: data from the French REAL.FR cohort. J Nutr Health Aging 2005; 9: 69-73.
• Goldman JG, Holden S: Treatment of psychosis and dementia in Parkinson's disease. Curr Treat Options Neurol 2014; 16: 281.
• Gomolin IH, Smith C, Jeitner TM: Cholinesterase inhibitors: applying pharmacokinetics to clinical decision making. Am J Geriatr Phar-macother 2011; 9: 259-263.
• Grossberg GT, Manes F, Allegri RF et al.: The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs 2013; 27: 469-478.
• Hogan DB: Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease. Can J Psychiatry 2014; 59: 618-623.
• Howard R, McShane R, Lindesay J et al.: Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012; 366: 893-903.
• Jann MW, Shirley KL, Small GW: Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41: 719-739.
• Karran E, Merckan M, De Strooper B: The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011; 10: 698-712.
• Kröger E, Van Marum R, Souverein P et al.: Treatment with rivastig-mine or galantamine and risk of urinary incontinence: results from a Dutch database study. Pharmacoepidemiol Drug Saf 2015; 24: 276-285.
• Lachaine J, Beauchemin C, Legault M et al.: Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. Can J Psychiatry 2011; 56: 596-604.
• Matthews FE, Arthur A, Barnes LE et al.; Medical Research Council Cognitive Function and Ageing Collaboration: A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet 2013; 382: 1405-1412. Mori E, Ikeda M, Kosaka K; Donepezil-DLB Study Investigators: Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012; 72: 41-52.
• Mossello E, Tonon E, Caleri V et al.: Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study. Arch Gerontol Geriatr Suppl 2004; (9): 297-307.
• Nordström P, Religa D, Wimo A et al.: The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. Eur Heart J 2013; 34: 2585-2591.
• Olazaran J, Reisberg B, Clare L et al.: Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy. Dement Geriatr Cogn Disord 2010; 30: 161-178.
• Olin JT, Bhatnagar V, Reyes P et al.: Safety and tolerability of rivastig-mine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int J Geriatr Psychiatry 2010; 25: 419-426.
• Periclou A, Ventura D, Rao N et al.: Pharmacokinetic study of meman-tine in healthy and renally impaired subjects. Clin Pharmacol Ther 2006; 79: 134-143.
• Qaseem A, Snow V, Cross T Jr. et al.: Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008; 148: 370-378.
• Rafii MS, Walsh S, Little JT et al.; Alzheimer's Disease Cooperative Study: A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 2011; 76: 1389-1394.
• Roman GC, Salloway S, Black SE et al.: Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke 2010; 41: 1213-1221.
• Rossor MN: Focal changes in Alzheimer's disease and cholinergic hypothesis. Lancet 19S3; 2: 465.
• Rowland JP, Rigby J, Harper AC et al.: Cardiovascular monitoring with acetylcholinesterase inhibitors: a clinical protocol. Adv Psychiatr Treat 2007; 13: 178-184.
• Schmitt FA, Farlow MR, Meng X et al.: Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. CNS Neurosci Ther 2010; 16: 330-336.
• Schneider LS, Dagerman KS, Higgins JPT et al.: Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011; 68: 991-998.
• Sobów T: Terapia funkcji poznawczych w chorobie Alzheimera. In: Rozpoznawanie i leczenie otępień. Rekomendacje Interdyscyplinarnej Grupy Ekspertów Rozpoznawania i Leczenia Otępień (IGERO 2006). Wydawnictwo Czelej, Lublin 2006: 53-59.
• Stephenson A, Seitz DP, Fischer HD et al.: Cholinesterase inhibitors and adverse pulmonary events in older people with chronic obstructive pulmonary disease and concomitant dementia: a population-based, cohort study. Drugs Aging 2012; 29: 213-223.
• Struble RG, Cork LC, Whitehouse PJ et al.: Cholinergic innervation in neuritic plaques. Science 1982; 216: 413-415.
• Tariot PN, Farlow MR, Grossberg et al.: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-324.
• Wesnes KA, Aarsland D, Ballard C et al.: Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2015; 30: 46-54.
• Winblad B, Kilander L, Eriksson S et al.; Severe Alzheimer's Disease Study Group: Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367: 1057-1065. (Erratum in: Lancet 2006; 367: 1980. Lancet 2006; 368: 1650).

• Document Type: article